NCT03835533 2024-04-12
PORTER
Parker Institute for Cancer Immunotherapy
Phase 1 Completed
Clinical Trials
4 trialsNCT03772288 2023-02-08
A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL)
Calithera Biosciences, Inc
Phase 1 Withdrawn
NCT03745807 2021-10-04
An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Completed
NCT04955262 2021-07-08
A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab
Nektar Therapeutics
Phase 1 Withdrawn